Aardvark Therapeutics, Inc. Common Stock AARD Income Statement
| FY'25 | ||
|---|---|---|
| $0— | ||
| $48.94M+182% | ||
| $13.79M+160% | ||
| $62.73M+175% | ||
| -$62.73M-175% | ||
| $5.13M+134% | ||
| -$57.59M-180% | ||
| -$2.93+43.1% | ||
| -$62.69M-175% | ||
| -$62.73M-175% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Aardvark Therapeutics, Inc. Common Stock profitable?
- Aardvark Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $69.9M over the trailing twelve months.
- What is Aardvark Therapeutics, Inc. Common Stock's earnings per share?
- Aardvark Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-3.21.
- Where does Aardvark Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Aardvark Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.